154 related articles for article (PubMed ID: 8895044)
1. Comparison of azithromycin and co-amoxiclav in the treatment of acute tracheobronchitis and acute infectious exacerbations of chronic bronchitis in adults. Azithromycin Study Group.
Biebuyck XA
J Int Med Res; 1996; 24(5):407-18. PubMed ID: 8895044
[TBL] [Abstract][Full Text] [Related]
2. Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study.
Gris P
J Antimicrob Chemother; 1996 Jun; 37 Suppl C():93-101. PubMed ID: 8818850
[TBL] [Abstract][Full Text] [Related]
3. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome.
Hoepelman IM; Möllers MJ; van Schie MH; Greefhorst AP; Schlösser NJ; Sinninghe Damsté EJ; van de Moosdijk CN; Dalinghaus WH; Eland ME; Mol SJ; Rozenberg-Arska M
Int J Antimicrob Agents; 1997 Jan; 9(3):141-6. PubMed ID: 9552709
[TBL] [Abstract][Full Text] [Related]
4. Open randomized study comparing doxycycline and co-amoxiclav in the treatment of acute suppurative tracheobronchitis in adults. The Collaborative Group of the Centre Universitaire de Medécine Générale de L'Université Libre de Bruxelles (CUMG-ULB) Investigators.
Sternon J
J Int Med Res; 1995; 23(5):369-76. PubMed ID: 8529780
[TBL] [Abstract][Full Text] [Related]
5. A randomized, comparative study to evaluate the efficacy and tolerability of a 3-day course of azithromycin versus a 10-day course of co-amoxiclav as treatment of adult patients with lower respiratory tract infections.
Zachariah J
J Antimicrob Chemother; 1996 Jun; 37 Suppl C():103-13. PubMed ID: 8818851
[TBL] [Abstract][Full Text] [Related]
6. An open, multicentre, comparative study of the efficacy and safety of azithromycin and co-amoxiclav in the treatment of upper and lower respiratory tract infections in children. The Paediatric Azithromycin Study Group.
Lauvau DV; Verbist L
J Int Med Res; 1997; 25(5):285-95. PubMed ID: 9364291
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, open label trial of azithromycin vs. amoxicillin/ clavulanate for the management of acute otitis media in children.
Aronovitz G
Pediatr Infect Dis J; 1996 Sep; 15(9 Suppl):S15-9. PubMed ID: 8878241
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, randomized, open label comparison of azithromycin and amoxicillin/clavulanate in acute otitis media among children attending day care or school.
Khurana CM
Pediatr Infect Dis J; 1996 Sep; 15(9 Suppl):S24-9. PubMed ID: 8878243
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind study of the clinical efficacy of 3 days of azithromycin compared with co-amoxiclav for the treatment of acute otitis media.
Dunne MW; Latiolais T; Lewis B; Pistorius B; Bottenfield G; Moore WH; Garrett A; Stewart TD; Aoki J; Spiegel C; Boettger D; Shemer A
J Antimicrob Chemother; 2003 Sep; 52(3):469-72. PubMed ID: 12888586
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections.
Ferwerda A; Moll HA; Hop WC; Kouwenberg JM; Tjon Pian Gi CV; Robben SG; de Groot R
J Antimicrob Chemother; 2001 Apr; 47(4):441-6. PubMed ID: 11266417
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of azithromycin versus amoxicillin/clavulanic acid in acute purulent exacerbation of chronic bronchitis.
Beghi G; Berni F; Carratù L; Casalini A; Consigli G; D'Antò M; Gioia V; Molino A; Paizis G; Vaghi A
J Chemother; 1995 Apr; 7(2):146-52. PubMed ID: 7666122
[TBL] [Abstract][Full Text] [Related]
12. Dirithromycin versus amoxiclav in the treatment of acute exacerbations of chronic bronchitis.
Van Royen P; Betz W; Heyrman J; Taziaux P; Van den Haute M; Poelman M
J Int Med Res; 1997; 25(1):33-40. PubMed ID: 9027671
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the efficacy, tolerability and safety of azithromycin and co-amoxiclav in the treatment of sinusitis in adults.
Clement PA; de Gandt JB
J Int Med Res; 1998; 26(2):66-75. PubMed ID: 9602984
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy, safety and tolerability of azithromycin and co-amoxiclav in the treatment of acute periapical abscesses.
Adriaenssen CF
J Int Med Res; 1998; 26(5):257-65. PubMed ID: 9924711
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis.
Cazzola M; Vinciguerra A; Beghi GF; Paizis G; Giura R; Madonini V; Fiorentini F; Consigli GF; Tonna M; Casalini A
J Chemother; 1995 Oct; 7(5):432-41. PubMed ID: 8596127
[TBL] [Abstract][Full Text] [Related]
16. A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections.
Hoepelman AI; Sips AP; van Helmond JL; van Barneveld PW; Neve AJ; Zwinkels M; Rozenberg-Arska M; Verhoef J
J Antimicrob Chemother; 1993 Jun; 31 Suppl E():147-52. PubMed ID: 8396086
[TBL] [Abstract][Full Text] [Related]
17. Multicentre evaluation of azithromycin in comparison with co-amoxiclav for the treatment of acute otitis media in children.
Schaad UB
J Antimicrob Chemother; 1993 Jun; 31 Suppl E():81-8. PubMed ID: 8396101
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of once-daily ceftibuten compared with co-amoxiclav in the treatment of acute bacterial sinusitis.
De Abate CA; Perrotta RJ; Dennington ML; Ziering RM
J Chemother; 1992 Dec; 4(6):358-63. PubMed ID: 1287138
[TBL] [Abstract][Full Text] [Related]
19. [The clinical and economic efficacies of short courses of azithromycin in acute sinusitis].
Karpov OI
Antibiot Khimioter; 1999; 44(10):28-32. PubMed ID: 10635419
[TBL] [Abstract][Full Text] [Related]
20. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
Starakis I; Gogos CA; Bassaris H
Int J Antimicrob Agents; 2004 Feb; 23(2):129-37. PubMed ID: 15013037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
